Early-stage non-small-cell lung cancer: Current perspectives in combined-modality therapy

Clinical Lung Cancer

Volumn 6, Issue 2, 2004, Pages 85-98

  Bunn Jr , Paul A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Adjuvant chemotherapy; Induction chemotherapy; Monoclonal antibodies; Radiation therapy; Tyrosine kinase inhibitors

Indexed keywords

ALKYLATING AGENT; BESTATIN; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; NITROSOUREA; PACLITAXEL; PLATINUM DERIVATIVE; TEGAFUR; UFT; VINBLASTINE; VINCA ALKALOID; VINDESINE;

ANEMIA; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; ESOPHAGITIS; FATALITY; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HAZARD ASSESSMENT; HUMAN; LEUKOPENIA; LONG TERM CARE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NAUSEA AND VOMITING; NEUTROPENIA; POSTOPERATIVE COMPLICATION; REVIEW; SEPSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TUMOR VOLUME;

EID: 7444256080     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2004.n.022     Document Type: Review

References (63)

1. American Cancer Society. Cancer Facts & Figures 2004. Atlanta:,GA: ACS, 2004.
2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-1717.
3. Hansen HH, Bunn PA Jr, Kelly K, eds. Treatment of non-small cell lung cancer. In: Lung Cancer Therapy Annual 3. London: Taylor & Francis Group, 2003:67-126.
4. Van Houtte P, Rocmans P, Smets P, et al. Postoperative radiation therapy in lung cancer: a controlled trial after resection of curative design. Int J Radiat Oncol Biol Phys 1980; 6: 983-986.
5. The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986; 315:1377-1381.
6. Lafitte JJ, Ribet ME, Prévost BM, et al. Postresection irradiation for T2 N0 M0 non-small cell carcinoma: A prospective, randomized study. Ann Thorac Surg 1996; 62:830-834.
7. Stephens RJ, Girling DJ, Bleehan NM, et al, for the Medical Research Council Lung Cancer Working Party. The role of post-operative radiation therapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Br J Cancer 1996; 74:632-639.
8. Dautzenberg B, Arriagada R, Chammard AB, et al, for the Groupe d'Etude et de Traitement des Cancers Bronchiques. A controlled study of postoperative radiation therapy for patients with completely resected nonsmall cell lung carcinoma. Cancer 1999; 86:265-273.
9. Debevec, M, Bitenc M, Vidmar S, et al. Postoperative radiation therapy for radically resected N2 non-small-cell lung cancer (NSCLC): randomized clinical study 1988-1992. Lung Cancer 1996; 14:99-107.
10. PORT Metaanalysis Trialists Group. Postoperative radiation therapy in non-small-cell lung cancer: systematic review and metaanalysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352:257-263.
11. PORT Meta-analysis Trialists Group. Postoperative radiation therapy for non-small cell lung cancer. (Cochrane Review). In: The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, 2004 (update on 1998 study published in Lancet 1998; 352:257-263).
12. Keller SM, Adak S, Wagner H, et al. for the Eastern Cooperative Oncology Group. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med 2000; 343;1217-1222.
13. Mountain CF, McMurtrey MJ, Frazier OH, et al. Present status of postoperative adjuvant therapy for lung cancer. Cancer Bull 1980; 32:108-112.
14. Girlling DJ, Stott H, Stephens RJ, et al. Fifteen-year follow-up of all patients in a study of post-operative chemotherapy for bronchial carcinoma. Br J Cancer 1985; 52:867-873.
15. Shields TW, Higgens GA, Humphrey EW, et al. Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung. Cancer 1982; 50:1713-1721.
16. Shields TW, Humphrey EW, Eastridge CE, et al. Adjuvant cancer chemotherapy after resection of carcinoma of the lung. Cancer 1977; 40:2057-2062.
17. Israel L, Bonadonna G, Sylvester R, and Members of the EORTC Lung Cancer Group. Controlled study with adjuvant radiation therapy, chemotherapy, immunotherapy, and chemoimmunotherapy in operable squamous carcinoma for the lung. In: Muggia F, Rozencweig M, eds. Lung Cancer: Progress in Therapeutic Research New York: Raven Press; 1979:443-452.
18. Mountain CF, Vincent RG, Sealy R, et al. A clinical trial of CCNU as surgical adjuvant treatment for patients with surgical stage I and stage II non-small cell lung cancer: preliminary findings. In: Muggia F, Rozencweig M, , eds. Lung Cancer: Progress in Therapeutic Research New York: Raven Press; 1979:421-431.
19. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311:899-909.
20. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003; 95:1453-1461.
21. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 351:351-360.
22. Waller D, Fairlamb DJ, Gower N, et al. The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC)-preliminary results in the surgical setting. Proc Am Soc Clin Oncol 2003; 22: 632 (Abstract #2543).
23. Kato H, Tsuboi M, Ohta M, et al, for the Lung Cancer Research Group. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I (T1N0M0, T2N0M0) adenocarcinoma of the lung. Proc Am Soc Clin Oncol 2003; 22:621 (Abstract #2498).
24. Ichinose Y, Genka K, Koike T, et al, for the NK421 Long Cancer Surgery Group. Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J Natl Cancer Inst 2003; 95:605-610.
25. Winton TL, Livingston R, Johnson D, et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10. Proc Am Soc Clin Oncol 2004; 23. Late breaking abstract available at http://www.asco.org. Abstract #7018.
26. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage 1B non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Proc Am Soc Clin Oncol 2004; 23. Late breaking abstract available at http://www.asco.org. Abstract #7019.
27. Tonato M, on behalf of the ALPI/EORTC-LCG Investigators. Final report of the Adjuvant Lung Project Italy (ALPI): an Italian/EORTC-LCG randomised trial of adjuvant chemotherapy in completely resected non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21:290a (Abstract #1157).
28. Bunn PA Jr. Chemotherapy for advanced non-small-cell lung cancer. who, what, when, why? J Clin Oncol 2002;20(Sept 15 suppl):23s-33s.
29. On-line Protocol Notice: 96-16/CALGB 9633, Closed, Accessed: 1/30/04.
30. Pisters KMW, Ginsberg RJ, Giroux DJ, et al, on behalf of the Bimodality Lung Oncology Team (BLOT). Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. J Thorac Cardiovasc Surg 2000; 119:429-439.
31. Martin J, Ginsberg RJ, Abolhoda A, et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 2001; 72:1149-1154.
32. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for subclassification and implications. J Clin Oncol 2000; 18: 2981-2989.
33. Pass HI, Pogrebniak HW, Steinberg SM, et al. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992; 53:992-998.
34. Rosell R, Gómez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330:153-158.
35. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21:1-6.
36. Rosell R, Gómez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 47:7-14.
37. Depierre A, Milleron B, Moro-Sibilot D, et al, from the French Thoracic Cooperative Group. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2001; 20:247-253.
38. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86:673-680.
39. Pisters K, Ginsberg R, Giroux D, et al. Bimodality lung oncology team (BLOT) trial of induction paclitaxel/carboplatin in early stage non-small cell lung cancer (NSCLC): long term followup of a phase II trial. Proc Am Soc Clin Oncol 2003; 22:633 (Abstract #2544).
40. Altorki NK, Kereszles RS, Port JL, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003; 21:2645-2650.
41. O'Brien MER, Splinter T, Smit EF, et al, for the EORTC Lung Cancer Group. Carboplatin and paclitaxel (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer: an EORTC phase II study (EORTC 08958). Eur J Cancer 2003; 39:1416-1422.
42. Siegenthaler MP, Pisters KM, Merriman KW, et al. Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann Thorac Surg 2001; 71:1105-1112.
43. Ettinger DS, Bepler G, Cox JD, et al. NCCN Non-small Cell Lung Cancer. Clinical Practice Guidelines in Oncology. v.1.2002. National Comprehensive Cancer Network.
44. Ettinger DS, Cox JD, Ginsberg RJ, et al. NCCN Non-Small-Cell Lung Cancer Practice Guidelines. Oncology 1996; 10(suppl):81-111.
45. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiation therapy followed by surgery for stages IIIA(N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group Phase II Study 8805. J Clin Oncol 1995; 13:1880-1892.
46. Albain K, Rusch V, Crowley J, et al, for the Southwest Oncology Group Lung Committee. Long-term survival after concurrent cisplatin/etoposide (PE) plus chest radiation therapy (RT) followed by surgery in bulky, stages IIIA(N2) and IIIB non-small cell lung cancer (NSCLC): 6-year outcomes from Southwest Oncology Group Study 8805. Proc Am Soc Clin Oncol 1999; 18:467a (Abstract #1801).
47. Albain KS, Scott CB, Rusch VR, et al. Phase III comparison of concurrent chemotherapy plus radiation therapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09). Proc Am Soc Clin Oncol 2003; 22:621 (Abstract #2497).
48. Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treatment Reviews 2004; 30:1-17.
49. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
50. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
51. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small call lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:310a (Abstract #1235).
52. Leslie WT, Bonomi PD. Novel treatments in non-small cell lung cancer. Hematol Oncol Clin N Am 2004; 18:245-267.
53. Herbst RS, Prager D, Hermann R, et al. TRIBUTE - a phase III trial of erlotinib HCL (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:617 (Abstract #7011).
54. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2004; 22:785-794.
55. Gatzemeier U, Pluzanska A, Szezesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:617 (Abstract #7010).
56. Mainwaring MG, Hainsworth JD, Gian VG, et al. Gefitinib (ZD1839) in the treatment of patients with advanced refractory non-small cell lung cancer (NSCLC): 250 patients treated at the Sarah Cannon Cancer Center. Proc Am Soc Clin Oncol 2003; 22:690 (Abstract #2774).
57. ErbituxTM (Cetuximab) [package insert]. 2004; 1/2/3. Accessed on-line 4/16/04.
58. Kelly K, Hanna N, Rosenberg A, et al. A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:644 (Abstract #2592).
59. Robert F. Blumenschein G, Dicke K, et al. Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003; 22:643 (Abstract #2587).
60. Gatzemeier U, Rosell R, Ramlau R, et al. Cetuximab in combination with cisplatin/vinorelbine vs. cisplatin/vinorelbine alone in the first-line treatment of patients with epidermal growth factor receptor positive advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:642 (Abstract #2582).
61. Kim ES, Mauer AM, Tran HT et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small tell lung cancer; final report. Proc Am Soc Clin Oncol 2003; 22:642 (Abstract #2581).
62. Lynch TJ, Lilenbaum R, Bonomi P, et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:624 (Abstract #7084).
63. Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:618 (Abstract #7012).